Cassava says two senior employees included in federal probes
Following years of accusations of scientific malfeasance, Alzheimer’s drug developer Cassava Sciences disclosed Monday that two of its senior employees are being investigated by the US Securities and...
View ArticleSeeking 'financial flexibility,' Esperion sells European royalty on...
Esperion has made another deal with a financial backer for an immediate cash haul in return for future revenue. Esperion received $304.7 million from the investor OMERS Life Sciences, the biotech...
View ArticleFTC investigates Teva over patents, doubling down on 'bogus' Orange Book...
The Federal Trade Commission has turned up the pressure in its patent probe, officially launching a civil investigation into a group of Teva’s drug patents that the agency claims are improperly listed...
View ArticleCartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises...
Cartesian Therapeutics, an mRNA cell therapy biotech, said its lead investigational medicine helped patients with an autoimmune condition that has caught the attention of many biopharmas in recent...
View ArticleSamsung Bio pulls in $1.06B manufacturing deal with unnamed US pharma company
Samsung Biologics has signed a manufacturing contract worth 1.46 trillion won ($1.06 billion) with an unnamed “large” US pharmaceutical company, making this at least the fourth major contract the...
View Article#EASD24: Weight loss readouts from Novo Nordisk, Boehringer Ingelheim,...
Companies large and small are set to present data on their next-generation weight loss drug candidates at the European Association for the Study of Diabetes annual meeting in Madrid, Spain. The...
View ArticleJ&J and Legend say Carvykti improved survival in earlier-line multiple myeloma
In a late-stage study, Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvykti improved survival in multiple myeloma patients who had received one to three prior lines of therapy compared to...
View ArticleCheckpoint Therapeutics refiles PD-L1 drug cosibelimab after FDA rejection
Checkpoint Therapeutics is taking a second shot at approval for its anti-PD-L1 candidate after the FDA rejected its first submission around seven months ago due to issues at a third-party manufacturer....
View ArticleFollowing a pivotal trial fail and layoffs, Ovid finds itself in a familiar spot
Last week, Ovid Therapeutics disclosed layoff plans in an SEC filing following a Phase 3 flop for its Takeda-partnered epilepsy program. The news sent its stock price $OVID down 70%. Ovid has been here...
View ArticleYuhan, Ubix ink licensing deal; Xenpozyme's royalty deal
Plus, news about Ipsen, Exelixis, Innovent, Codexis, Crosswalk Therapeutics and J&J: Yuhan licenses prostate cancer drug: The biotech will pay Seoul-based Ubix Therapeutics $3.6 million upfront and...
View ArticleClik here to view.
Moderna wins $176M BARDA award to finance bird flu work
Moderna received a significant boost from the federal government, snagging a $176 million contract to help advance a bird flu vaccine. The award, which was granted by the Biomedical Advanced Research...
View ArticleAs confidence falls, biopharma companies take precautions with Chinese...
Geopolitical tensions and threats of decoupling have led to a steep decline in American companies’ confidence in working with Chinese partners, although few have taken steps to end relationships,...
View Article'Optimizing R&D structure is also on the horizon, without exception,' new...
Sumitomo Pharma CEO Toru Kimura says that he sees the need to streamline the company’s business and product lineup, and is considering steps including job cuts. He’s also looking at how to optimize the...
View ArticleEli Lilly wins long-awaited approval for Alzheimer’s drug
After decades of trying to develop a treatment for Alzheimer’s disease, Eli Lilly has finally won FDA approval for its drug donanemab, which will be marketed as Kisunla. An approval was originally...
View ArticleLondon court upholds Moderna patent in vaccine dispute with Pfizer, but...
Moderna’s long-running patent dispute with Pfizer and BioNTech intensified Tuesday after London’s High Court of Justice upheld one of Moderna’s key mRNA patents, but invalidated another. The court...
View ArticleEmergent announces $250M in contract modifications from the US
Emergent BioSolutions scored more than $250 million in government contract modifications for four medical countermeasures, including anthrax, smallpox and botulism vaccines. As part of the contract,...
View ArticleClik here to view.
GSK licenses full rights to CureVac’s flu, Covid mRNA vaccines for $429M in...
GSK is handing mRNA vaccine partner CureVac €400 million ($429 million) upfront to take over full rights to the influenza and Covid vaccine candidates they have been collaborating on, while walking...
View ArticleClik here to view.
Beacon raises $170M to take on J&J in ocular gene therapy
Transatlantic biotech Beacon Therapeutics has raised $170 million to potentially bring a rare ophthalmology gene therapy to market in a competition with Johnson & Johnson. J&J is ahead of...
View ArticleClik here to view.
Flagship appears to boost target of eighth fund by up to $500M
Flagship Pioneering, the sprawling life sciences investor and startup incubator, appears to be seeking more capital than originally planned for its eighth fund. The Boston-area firm is raising up to...
View ArticleSanofi and Regeneron’s Dupixent wins EU nod in COPD ahead of September PDUFA
Sanofi and Regeneron’s Dupixent has notched another indication in the EU, this time for a common lung disease, marking the first-ever targeted therapy for the condition in the region. The French...
View Article